The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback